Results 81 to 90 of about 15,879 (168)

SLC7A5 promotes colorectal cancer liver metastasis by reprogramming tryptophan metabolism through the Kyn/XANA‒AhR axis and reshaping the immune microenvironment

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
SLC7A5‒Kyn/XANA signalling activates AhR to drive EMT and metastatsis. SLC7A5 knockdown enhances macrophage antigen presentation and reverses CD8+ T‐cell exhaustion. SLC7A5 knockdown induces antigen‐driven and IgG‐secreting B‐cell clonal expansion. Combination of SLC7A5 inhibition and anti‐PD‐1 therapy offers clinical targeting.
Yaohao Luo, Lei Li, Shanbao Li, Xinshuai Wang, Zeping He, Fangbin Song, Jun Qin, Jinyan Zhang, Junming Xu   +8 more
wiley   +1 more source

The evolving landscape of the Warburg effect in gastric cancer: From molecular mechanisms to targeted therapy

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Hypoxia, oncogenic signaling, transcriptional and epigenetic remodeling, and H. pylori–microbiota interactions drive the Warburg effect in gastric cancer. Enhanced glycolysis and lactate export support biosynthesis, remodel the tumor microenvironment, promote stromal activation and immune suppression, and reveal actionable biomarkers and therapeutic ...
Guanmo Liu, Pan Li, Zizhuo Li, Jie Li, Chenggang Zhang, Yihua Wang, Weiming Kang, Xin Ye   +7 more
wiley   +1 more source

Neutrophil‐based immunotherapy: A metabolic lens on mechanisms and therapeutic implications

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
TAN metabolic reprogramming critically contributes to tumour immune evasion. A 4‑Tier TAN‑MetaC classification framework is proposed, along with an overview of translational opportunities and bottlenecks for TAN metabolism‑targeted immunotherapies. Abstract Background Tumor‐associated neutrophils (TANs) serve as pivotal immune modulators in the tumor ...
Wenchao Xu, Yu Su, Li Zhou, Jianzhou Liu, Junchao Guo   +4 more
wiley   +1 more source

Tumor‐Responsive PLGA‐SS‐HA Nanoparticles for Zinc Complex Delivery Suppress Prostate Cancer via TR3/FTH1 Pathway

Macromolecular Materials and Engineering, Volume 311, Issue 8, August 2026.
A tumor‐responsive PLGA‐SS‐HA nanoplatform enables glutathione‐triggered delivery of zinc complexes to prostate cancer cells. Enhanced intracellular zinc accumulation induces oxidative stress, mitochondrial dysfunction, and apoptosis through activation of the TR3/FTH1 signaling pathway.
Ding Ma, Sheng Ge, Ruimin Ren, Yongqiang Fu   +3 more
wiley   +1 more source

Early‐Onset Prostate Cancer: Epidemiology, Risk Factors, Biology, Clinical Features, Management, and Early Detection

MedComm, Volume 7, Issue 8, August 2026.
EOPC is a distinct clinicopathological entity separable from SOPC, differing fundamentally in genetic susceptibility, TMPRSS2:ERG fusion frequency, and survival outcomes. Although research remains nascent, this review provides the first comprehensive synthesis of current evidence, offering a critical foundation to guide future investigations into this ...
Xingyu Xiong, Weizhen Zhu, Weichao Huang, Shiyu Zhang, Qi Deng, Jie Yang, Hang Xu, Qiang Wei, Lu Yang   +8 more
wiley   +1 more source

Cardiovascular Diseases and Cancer: Convergent Proteostasis Networks at the Crossroads of Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 8, August 2026.
The disruption of proteostasis, encompassing the ubiquitin–proteasome system, autophagy, UPR/ER stress, and chaperone function, represents a fundamental mechanism shared by both cancer and cardiovascular diseases. While these pathways frequently facilitate tumor progression, they are crucial for maintaining proteostasis in cardiac tissue. Consequently,
Jacob Eli García Torres, Norbert Frey, Ashraf Yusuf Rangrez   +2 more
wiley   +1 more source

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 8, August 2026.
The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng, Shuiquan Li, Zhigang Zhang, Mengke Niu, Jing Fei, Jiaojiao Zhang, Jianwei Zhou, Kongming Wu, Ming Yi, Tianye Li   +9 more
wiley   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, Volume 86, Issue 11, Page 1187-1194, August 2026.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source

Immune-inflammation index as prognostic markers in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Qin Z, Liu R, Jing S, Guo C, Li W.
europepmc   +1 more source